This segment focuses on the development and commercialization of MYCAPSSA, an oral octreotide capsule for the treatment of acromegaly. Research and development activities are centered on improving the oral delivery of peptide drugs using Chiasma's proprietary Transient Permeability Enhancer (TPE) technology. The TPE technology enables the oral absorption of drugs that are typically administered via injection. MYCAPSSA offers a convenient alternative to injectable somatostatin analogs, improving patient compliance and quality of life. Clinical trials have demonstrated the efficacy and safety of MYCAPSSA in maintaining biochemical control in acromegaly patients. The company collaborates with healthcare providers and patient advocacy groups to raise awareness and improve access to treatment. Future opportunities include expanding the use of MYCAPSSA to other indications and developing new oral peptide therapies.